DBV Technologies S.A. (NASDAQ:DBVT) Stock Has Average Target Price of $48.50

DBV Technologies S.A. (NASDAQ:DBVT) has received a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $48.50.

A number of analysts have recently issued reports on DBVT shares. Citizens Jmp lifted their target price on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 30th. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Cantor Fitzgerald restated an “overweight” rating on shares of DBV Technologies in a research note on Thursday, September 10th. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Finally, Weiss Ratings downgraded DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th.

Institutional Trading of DBV Technologies

A number of hedge funds have recently made changes to their positions in DBVT. Vivo Capital LLC raised its holdings in DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after acquiring an additional 205,943 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in DBV Technologies during the 1st quarter worth $21,159,000. Perceptive Advisors LLC bought a new stake in shares of DBV Technologies in the 1st quarter worth about $20,146,000. Atika Capital Management LLC increased its position in shares of DBV Technologies by 31.1% in the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company’s stock worth $5,667,000 after purchasing an additional 64,419 shares during the last quarter. Finally, Elmind Capital LP bought a new stake in shares of DBV Technologies in the 1st quarter worth about $5,536,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Price Performance

Shares of DBVT stock opened at $11.56 on Friday. The company’s fifty day moving average price is $13.51 and its two-hundred day moving average price is $16.89. The firm has a market capitalization of $726.89 million, a P/E ratio of -3.29 and a beta of -0.95. DBV Technologies has a 12 month low of $8.90 and a 12 month high of $26.18.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.